Contents

01 September 2010
Vol 2, Issue 47

About The Cover

Cover image expansion

ONLINE COVER A Human Kidney. The need for sensitive and specific biomarkers of kidney damage led to the development of the U.S. Food and Drug Administration's new process for biomarker qualification. Whereas biomarkers for determining the right patient population for a certain drug are often qualified for use during the drug's clinical trial, this new regulatory process is independent of the development of specific drugs, as described by Goodsaid and Mendrick in a Perspective. [CREDIT: C. BICKEL/SCIENCE TRANSLATIONAL MEDICINE]